Category: China

AI Dream (King Koil and Serta China) provides Wuhan hospitals with bedding essentials

Mattress company donated supplies to emergency hospitals and raises funds for Covid-19 relief.

Raised for the Wuhan Charity Foundation
Bedding manufacturer AI Dream (King Koil and Serta China) has masterminded a ‘bed-in-a-box’ program to help the areas of Wuhan most affected by the Covid-19 pandemic. The Chinese firm has donated ~3000 items of bedding, including pillows, mattresses and beds, to temporary hospitals.
In a separate initiative, the company held a charity pillow sale that raised $650k for the Wuhan Charity Foundation – an organization running coronavirus relief projects in the city.
The company has taken steps to look after its network of distributors in Wuhan and elsewhere. Between February and April, AI Dream provided a contribution to their rent costs, and helped to pay their employees’ salaries.
Established in 2000, King Koil China is a premium manufacturer and retailer of mattresses for the Chinese market. The Shanghai-based company owns an exclusive license within the country for major international brands including King Koil and Life Balance. It is the premier supplier of sleep products to China’s expanding luxury-hotel sector.
Serta entered China in 1998 and has grown into a leader in the Chinese mattress market. Serta China is the exclusive licensee of the Serta Brand in China. Based in Shenzhen, Serta China has more than 1,600 branded outlets across the country.

Chinese efforts focus on healthcare support

Three charities backed in China offering support to healthcare professionals.

Medical masks donated
Since the outbreak of the novel coronavirus in December 2019, China has been at the forefront of developing treatments and initiating the extreme social measures that we are now seeing around the world to bring it under control. At the head of this effort from the start have been dedicated healthcare professionals who have battled day-and-night in completely unprecedented circumstances. To help support this effort, our Chinese team has made donations to three foundations that are heavily involved in supporting the ongoing work of hospitals and frontline medical staff.
The Hubei Charity Federation(“HBCF”) is the official government foundation for Wuhan city in Hubei province, ground-zero in the outbreak of this global pandemic. From the start, the Jinyintan Hospital in Wuhan has fought to contain the outbreak, treating thousands of Covid-19 patients and dealing with high infection rates amongst its medical staff. The Hospital head, Dingyu Zhang became a nationwide hero and has led a staff of more than 500 physicians, nurses and volunteers in the city’s three-month battle against the virus. Our donation to HBCF has been allocated to the Jinyintan Hospital to support the medical staff in their ongoing battle.
The Shanghai Charity Foundation (“SCF”) is the official channel for Covid-19 relief and epidemic control efforts in Shanghai and is also supporting charitable activities to Hubei province. It has recently been at the forefront of epidemic control against the spate of new imported cases in the city.
Our final donation is to The Shanghai United Foundation (“SUF”), a ten-year old institution that is now running Covid-19 relief efforts across the country. The Foundation is prioritising efforts on medical staff, patients, children, local community relief and healthcare professionals. So far, the SUF has completed 18 anti-epidemic public welfare projects and is implementing 22 more. It also provided anti-epidemic materials for 138 rural kindergartens and primary schools in China with its ‘Handwashing Project’. So far, SUF has donated a total of 5,000 pieces of medical protective glasses or protective masks, 73,000 pairs of medical gloves, 13,000 pieces of medical protective suits, 620,000 medical masks, 600 disinfection lamps and food supplies. Our donation has helped support SUF’s current initiative – providing PPE to Suifenhe port of entry and other cities in Heilongjiang province, where hundreds of new cases were reported in April.

Laird acclaimed for swift coronavirus response in China

British tech firm takes decisive action to reopen plants with full raft of protective measures.

Top 10

Laird’s plants placed in the top 10% of all factories that had resumed production by the Chinese government

Laird, a British technology business, has been praised for the resilience of its Chinese operation in the face of the Covid-19 pandemic.
The company was able to return 98 percent of its workforce to their jobs by February 28, after putting appropriate safeguards in place. The company received widespread recognition from local and national news sources for its swift reopening of factories closed down by the virus in January 2020.
The rapid return to operation was made possible through a recovery plan executed across Laird’s four factories, with the help of a specially convened Covid task force. An early priority was securing ample supplies of protective masks, which were mailed to employees during the Chinese New Year break.
The task force maintained close contact with the workforce, answering questions and allaying fears. Workers were reassured that they would be paid even if they were unable to come to work. Suppliers were also kept informed about the recovery plan, ensuring orders were not cancelled.
New protective measures on the factory floor include staggering start times and breaks, disinfecting the plant, taking the temperature of workers twice daily, and installing partitions to separate employees by at least 1.5 meters.
Throughout the process, the company consulted with the Chinese government, which sent a hospital team to audit the Covid mitigation program. It placed Laird’s plants in the top 10% of all factories that had resumed production.
Laird has incorporated the lessons learned in China into its working practices at other locations – including sites across Europe and North America. It has also been able to share valuable insights about how to tackle Covid-19 with other companies in the Advent portfolio.
Laird is a global engineering technology group that provides solutions in the fields of electromagnetic integrity, thermal performance and connectivity.

BioDuro’s quest for a nanobody therapy to combat coronavirus

BioDuro is harnessing its world-leading biopharmaceutical expertise to fight the coronavirus pandemic. A specialized team is leveraging the firm’s acclaimed biologics discovery program to find an effective nanobody therapy for Covid-19 patients.

Human synthetic antibodies screened
The program is sponsored by the Global Health Drug Discovery Institute (GHDDI), which is jointly founded by the Bill and Melinda Gates Foundation, Tsinghua University and Beijing Municipal Government.
BioDuro’s initiative uses advanced synthetic antibody technology to find a way of blocking the virus’s entry and fusion into human cells. This process involves screening more than 10 billion human synthetic antibodies, all generated using Artificial Intelligence (AI) computing and high-speed DNA mutagenesis technology.
The aim of the program is to discover which antibody disrupts the Covid-19 virus most optimally. This will enable scientists to produce a nanobody: an antibody that contains only the single, tiny unit needed for recognition and disruption of Covid-19 targets.
Thanks to their small size, nanobodies are extremely effective at penetrating human tissue – such as when delivered in a spray to the lungs – ensuring a high dose is received.
The dedicated Covid-19 team includes scientists from a wide range of specialisms, including AI, phage display, assay development, protein purification, cell biology and biochemistry.
In a separate initiative, BioDuro has also partnered with the UC San Diego Health System and Scripps Health – a nonprofit health system based in the city – to augment their hospitals’ supply of personal protective equipment (PPE), and produce additional stocks of hand sanitizer.
Headquartered in San Diego, CA, USA, BioDuro is a leading global life-sciences contract research and development organization. The company has cutting-edge facilities in Beijing and Shanghai, China, and a fourth site is under construction in Wuxi.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google